GWAS and eQTL studies identified thousands of genetic variants associated with complex traits and gene expression. Despite the important role of environmental exposures in complex traits, only a limited number of environmental factors are measured in these studies. Measuring molecular phenotypes in tightly controlled cellular environments provides a more tractable setting to study geneenvironment interactions in the absence of other confounding variables.
Introduction
The vascular endothelium refers to the single layer of cells lining blood vessels which form an interface between the blood and the rest of the body. The endothelium plays an important role in coagulation, 
Results

Exposure of endothelial cells to environmental perturbations leads to changes in gene expression and chromatin accessibility
To determine the impact of genetic variation on endothelial cell response to environmental perturbations, we treated human umbilical vein endothelial cells (HUVECs) from 17 unrelated, healthy donors with 4 compounds (dexamethasone, retinoic acid, caffeine, and selenium) and 2 vehicle controls. These treatments have been associated with cardiovascular disease and/or endothelial dysfunction [17, 40, 50, 52] and have been shown in a previous study [35] to produce strong transcriptional responses in HUVECs. We then assessed changes in gene expression with RNA-seq in all samples and chromatin accessibility with ATACseq in four samples at six hours following treatment ( Figure 1A ). We used DESeq2 [30] to identify differentially expressed genes (DE genes) and differentially accessible regions (DARs) in chromatin following the environmental perturbations. Each treatment caused significant transcriptional responses, with greater than 2500 differentially expressed genes in each environment (Benjamini-Hochberg (BH) FDR < 10%, | log 2 FC| > 0.25) ( Table 1) . By gene ontology analysis, we identified an enrichment of differentially expressed genes implicated in biological processes relevant for endothelial function. For example, response to wounding is enriched in genes downregulated in response to dexamethasone, and regulation of blood vessel diameter is enriched in genes downregulated in response to retinoic acid ( Supplementary Table S1 ).
Across the four samples for which ATAC-seq was obtained, we identified between 133 and 1038 DARs in a given treatment condition ( Table 1 ). The smaller number of DARs, compared to DE genes, could be due to the timescale at which we measured response, the increased stochasticity of chromatin opening and closing relative to gene expression, and/or insufficient statistical power. We used chromHMM [16] chromatin states derived from ENCODE HUVECs histone marks [15] to annotate DARs. We found an enrichment of DARs in strong enhancer regions in dexamethasone, retinoic acid, and selenium (OR = 5.31, 3.89, and 3.51, respectively. p < 2.2 × 10 −16 for all). However, caffeine DARs are only slightly enriched in strong enhancers (OR = 1.15, p = 0.018). Instead, DARs in caffeine are most enriched for active promoters (OR = 2.5, p < 2.2 × 10 −16 ). This difference between treatments could indicate that different type of factors are involved in each response.
To investigate the relationship between differential chromatin accessibility and transcriptional response, we calculated the enrichment of DE genes within 50kb of a DAR. DE genes in all treatments were significantly enriched near DARs identified in the same treatment. The greatest enrichments were found for dexamethasone and retinoic acid with odds ratios of 3.35 and 3.99, respectively ( Figure 1B ,C and Supplementary Figure S1; Fisher's exact test; p < 5.6 × 10 −8 ). The significant enrichment for DE genes among DARs in dexamethasone and retinoic acid could be due to their mechanism of action, specifically that both treatments are known to work largely through specific nuclear receptors that bind the DNA and influence gene expression directly. Overall these results suggest that changes in chromatin accessibility are an important mechanism through which cells regulate gene expression in response to environmental perturbation. 
Specific transcription factors regulate response to treatment
In addition to informing on open chromatin, ATAC-seq data can be analyzed to characterize the transcription factor landscape governing response to treatment. This is particularly important given that the vast majority of genetic variants found to influence complex traits act through gene regulatory regions. In order to identify transcription factors controlling response to each treatment, we used CENTIPEDE [41] to perform footprinting analysis on the ATAC-seq data. Across all conditions, we identified a total of 882 active transcription factors, defined as those with motifs that have CENTIPEDE footprints and are associated with open chromatin (Methods, Supplementary Table S6 , see examples in Figure 2A ). We hypothesized that transcription factors which are important in the regulation of a particular treatment will be more likely to be found in DARs. The factors with the greatest enrichments in DARs are shown in Figure 2B . We refer to these enriched factors as response factors. We identified 724 factors with footprints in regions that become more accessible after treatment and 259 factors in regions that are less accessible after treatment (Table 2) . For well-studied treatments, like retinoic acid and dexamethasone, our approach identified transcription factors known to be central to the regulation of gene expression in response to those treatments. For example, the top retinoic acid response factors were the retinoic acid receptor along with two interferon regulatory factors (IRF), all of which has previously been shown to be influenced by retinoic acid [4, 8, 31] (Figure 2A ). For dexamethasone, the androgen receptor (AR), glucocorticoid receptor (GR), and progesterone receptor (PR) have similar binding sites and likely all represent sites of GR binding [47, 48] . While for these treatments we have prior information on the major mechanisms that regulate the cellular response, for caffeine and selenium less is known, and our data can be used to identify the relevant factors ( Supplementary Table S3 ). In response to selenium treatment the top enriched factors are in regions that become less accessible after treatment. Caffeine has been shown to induce apoptosis in HUVECs [29, 32] , and one of the top caffeine response factors is Sp1, which has been implicated in apoptotic pathways [10, 24] . Identifying latent environmental factors in large scale eQTL datasets from vascular tissues
Large-scale efforts to identify expression quantitative trait loci (eQTLs), such as GTEx [1] , have discovered genetic regulators of gene expression in many different tissues, including three types of artery. However, GTEx samples likely represent a composite of different environmental exposures. Here we propose that latent, unobserved environmental factors contribute to eQTL effects detected in GTEx and that some of these eQTLs may represent cases of significant interaction effects in specific environmental contexts. To indirectly test this hypothesis, we considered that interactions with latent environments represented by our four in vitro treatments (retinoic acid, caffeine, selenium and dexamethasone) would be enriched in response factor binding sites. We used centiSNPs [35] , an extension of the CENTIPEDE framework, to annotate SNPs in response factor footprints, as these SNPs are most likely to disrupt transcription factor binding and modify the transcriptional response. We found that out of 4,422,115 SNPs in footprints for active factors, 76% are in footprints for response factors for at least one of the treatments. We then estimated enrichments for our treatment-specific annotations in eQTLs from the artery samples in GTEx.
Using the EM-DAP1 algorithm implemented in the software package TORUS [53] , we found enrichment of eQTLs in footprints for dexamethasone, retinoic acid, and caffeine response factors, but not for selenium ( Figure 3A ). These results suggest that exposure to retinoic acid, caffeine, and dexamethasone (or a closely related factor; e.g. cortisol elevated by stress) are represented as latent environments in the GTEx samples and can modulate eQTL effects.
Latent environments in Coronary Artery Disease
To identify which conditions may be enriched for putative latent GxE in coronary artery disease (CAD) we performed an enrichment analysis for SNPs in footprints for response factors using CAD GWAS data [37] ( Figure 3B ). Among the treatment conditions we explored, we found a strikingly high enrichment of 8.17fold for CAD associated variants that are found in caffeine response factor footprints. This enrichment is also significantly higher than the one found for footprints that are identified in the control condition (2.86fold increase), which represent regulatory variants that do not interact with the treatments considered here. This suggests a large number of latent GxE effects in cardiovascular disease risk.
To further dissect the molecular mechanism for GxE in CAD risk, we integrated GTEx artery eQTLs with the GWAS summary statistics and GxE effects in gene expression in our data. We first performed colocalization of GTEx eQTLs with CAD GWAS hits using enloc [54] (Methods) and identified 168 SNPgene pairs. Forty GTEx tissues had at least 1 colocalized eQTL. The most represented tissues for colocalized SNPs were the aorta and tibial artery with 56 and 28 colocalized SNPs, respectively ( Supplementary Table  S4 ). Of the colocalized genes, 14 can be tested for reQTL in our data and six have a reQTL in at least one of the treatment conditions considered (permutation p<0.05, see Supplementary TableS5). Although with our sample size we do not have the power to detect genome-wide significant signals, we provide an example of one of the top reQTL in SWAP70 for caffeine ( Figure 3C ). SWAP70 is implicated in endothelial sprouting in vivo [13] and the gene is significantly downregulated (BH FDR < 10%) in response to caffeine in HUVECs. The reQTL, rs10840293, is in a footprint for the caffeine response factor AFT2. These reQTLs suggest specific mechanisms through which environmental exposures can increase or decrease the genetic risk for for coronary artery disease. We further investigated whether the environmental interaction with the risk genotype results in amplification or buffering of the disease risk. Figure 3D shows the risk z-score from the CAD GWAS study, with a positive sign if the risk allele is associated with higher gene expression in GTEx (horizontal axis) plotted against the interaction effect in endothelial cells from our reQTL mapping. For four colocalized reQTLs, the treatment amplifies the genetic effect (positive value on the y-axis) on gene expression and in all these cases, higher expression is associated with increased risk (positive value on the x axis). For six colocalized signals, the treatment reduces the genetic effect on disease risk (negative values on the y-axis) and in most cases (4 out of 6) lower expression of the gene is associated with increased risk. For example, lower expression of SWAP70 is associated with increased risk, however, in the presence of caffeine, the effect of the risk variant is significantly reduced (negative sign for the reQTL), thus caffeine buffers the genetic effect on disease risk. These results show that environmental effects on disease risk are contingent on the individual's genotype, with certain exposures amplifying a specific genetic risk but buffering others.
Discussion
Vascular endothelial dysfunction has been implicated in a variety of cardiovascular and non-cardiovascular diseases. Here we have characterized the transcriptional and chromatin landscape in endothelial cells exposed to dexamethasone, retinoic acid, caffeine, and selenium.
While all of these treatments cause significant changes in gene expression and chromatin accessibility, they act through varied pathways. Dexamethasone and retinoic acid are steroid hormones whose action at the molecular and transcriptional level has been well-studied [11, 38] . Caffeine and selenium have been investigated at the molecular level, particularly with regard to caffeine's role in inhibiting the breakdown of cAMP and selenium's role as a cofactor [14, 44] . However, the regulators of gene expression response to these compounds are less characterized, especially in endothelial cells. We were able to confirm with retinoic acid and dexamethasone that our approach in analyzing ATAC-seq data identifies biologically relevant response factors, as we found enrichment of known intracellular steroid receptors like the retinoic acid receptor and glucocorticoid receptor. Upon extension of this framework to caffeine and selenium, we identified key response factors for these treatments that were previously unknown (e.g. Sp1 and Sp3 for caffeine).
Combining the ATAC-seq data with known genetic variation in human populations, we have generated a set of annotations for genetic variants in the footprints of treatment response factors (1300 motifs genome-wide) which may affect binding and therefore gene expression response in the different conditions considered. Using this annotation in combination with large scale genetic studies of gene expression (GTEx) and CAD risk (Cardiogram), we detected potential latent environmental effects and assigned a putative mechanism of action for variants associated with these molecular and organismal traits, through disruption of transcription factor binding. We found that dexamethasone, retinoic acid, and caffeine were enriched in GTEx eQTLs from three different arteries in our response factor annotations. This is not surprising given the widespread use of caffeine in the general population and the expression of the glucocorticoid receptor and retinoic acid receptor in most GTEx tissues [1] . Interestingly, we did not find an enrichment for the selenium annotation, which is expected considering that we are only exposed to limited amounts of selenium on a daily basis. Our observation that that genetic loci associated with risk of coronary artery disease are highly enriched in the binding sites of transcription factors that regulate response to caffeine, suggests that caffeine modulates coronary artery disease risk. This is an intriguing finding given the extensive number of studies that have explored the link between caffeine, coffee consumption, and heart disease [12, 51] .
Here, we developed a novel conceptual framework that combines information on specific environmental perturbations collected in vitro with large scale heterogeneous datasets interrogating genetic effects on both molecular and organismal phenotypes. While our study demonstrates that there is a significant enrichment for genetic associations in context specific regulatory annotations, our small sample size had limited power to directly validate these latent GxE effects. Nevertheless, this approach can be used to guide the design of future studies to directly test for GxE. In our proof of principle, we show that we can leverage molecular phenotyping data in response to tightly controlled treatments to characterize the complex interplay between genotypes and environment and their role in complex traits, highlighting the importance of latent environmental exposures in large-scale datasets.
Methods
Cell Culture 14 primary HUVECs were isolated from human umbilical cord tissue collected shortly following birth. Umbilical cord tissue specimens were obtained from healthy full-term pregnant women, admitted to DMC Hutzel Women's Hospital (Detroit, Michigan). All specimens for this study were collected following guidelines approved by the institutional review board (#013213MP4E) of Wayne State University. Cord specimens, between 10 and 30 cm in length, were first rinsed with warm PBS and a blunt-ended needle was inserted into the umbilical vein at one end of the cord, and subsequently clamped in place. The cord was then purged to remove any excess blood from the vein. The other end of the cord was then sealed, in a manner identical to the first end, and pre-warmed 0.25% trypsin-EDTA (Gibco) was then injected into the vein. Following a 20 minute incubation, at 37 • C, detached HUVECs were rinsed from the vein, collected by centrifugation, counted, and seeded into an appropriate vessel at 10,000 cells/cm 2 , in EGM-2 growth medium (Lonza). Expanded cultures were cryopreserved prior to be used in the experiments. For additional 3 HUVEC lines from a previous study [35] we collected ATAC-seq data and used previously published RNA-seq data (dbGaP accession number phs001176.v1.p1).
Treatments
Treatment concentrations were the same as used in [35] and were derived from the Clinical Guidelines Mayo Clinic Reference Levels (http://www.mayomedicallaboratories.com) and the CDC National Biomonitoring Report Reference Levels (http://www.cdc.gov/biomonitoring/). Concentrations were 1 × 10 −6 M for dexamethasone, 1 × 10 −8 M for retinoic acid, 1.16 × 10 −3 M for caffeine, and 1 × 10 −5 M for selenium. Vehicle controls were included to represent the solvent used to prepare the different treatments, either ethanol (1µl of EtOH per 10,000µl of culturing media) or water.
Each individual cell line was treated on a separate day. Culturing conditions were the same as those found in [35] . Specifically, three days before treatment, cells were plated (to passage 7) in 8 wells in 6well plates at 5,000/cm 2 in EGM-2. Following a 24 hour recovery period, the medium was changed to a "starvation medium", composed of phenol-red free EGM-2, without Hydrocortisone and Vitamin C and supplemented with 2% CS-FBS. Cell starvation was continued for 48 hour prior to treatment. For each individual cell line, control treatments were performed in duplicate. Cells were treated for 6 hours and then were collected by scraping the plate on ice. For four cell lines, each well was counted in order to remove 50,000 cells to be used for ATAC-seq while the rest were used for RNA sequencing.
RNA Library Preparation
Treated cells were collected by centrifugation at 2000 rpm and washed 2x using ice cold PBS. Collected pellets were lysed on the plate, using Lysis/Binding Buffer (Ambion), and frozen at -80 • . Poly-adenylated mRNAs were subsequently isolated from thawed lysates using the Dynabeads mRNA Direct Kit (Ambion) and following the manufacturer instructions. RNA-seq libraries were prepared using a protocol modified from the NEBNext Ultradirectional (NEB) library preparation protocol to use 96 Barcodes from BIOO-Scientific added by ligation, as described in [33] . The individual libraries were quantified using the KAPA real-time PCR system, following the manufacturer instructions and using a custom-made series of standards obtained from serial dilutions of the phi-X DNA (Illumina). Libraries were pooled and sequenced in multiple sequencing runs for an average of 50M 300bp PE reads.
ATAC-seq Library Preparation
We followed the protocol by [7] to lyse 50,000 cells and prepare ATAC-seq libraries, with the exception that we used the Illumina Nextera Index Kit (Cat #15055290) in the PCR enrichment step. For 3 of the 4 individual cell lines (LP-001, LP-002 and H288-L), the cells were not lysed with 0.1% IGEPAL CA-630 before adding the transposase to begin the ATAC-seq protocol. Individual library fragment distributions were assessed on the Agilent Bioanalyzer and pooling proportions were determined using the qPCR Kapa library quantification kit (KAPA Biosystems). Library pools were run on the Illumina NextSeq 500 Desktop sequencer in the Luca/Pique-Regi laboratory. Barcoded libraries of ATAC-seq samples were pooled and sequenced in multiple sequencing runs for an average coverage of 130M reads.
Alignment of RNA and ATAC-seq
Reads were aligned to the GRCh37 human reference genome using HISAT2 [26] (https://ccb.jhu.edu/ software/hisat2/index.shtml, version hisat2-2.0.4), and the human reference genome(GRCh37) with the following options:
HISAT2 -x <genome> -1 <fastq_R1.gz> -2 <fastq_R2.gz> where <genome> represents the location of the genome file (genome snp for ATAC-seq alignment, genome snp tran for RNA-seq alignment), and <fastqs R1.gz> and <fastqs R2.gz> represent that sample's fastq files.
The multiple sequencing runs were merged for each samples using samtools (version 2.25.0). We removed PCR duplicates and further removed reads with a quality score of < 10 (equating to reads mapped to multiple locations) for the RNA-sequencing analysis, only.
Differential Gene Expression Analysis
To identify differentially expressed (DE) genes, we used DESeq2 [30] (R version 3.2.1, DESeq2 version 1.8.1). Gene annotations from Ensembl version 75 were used and transcripts with fewer than 20 reads total were discarded. coverageBed was utilized to count reads with -s to account for strandedness and -split for BED12 input. The counts were then utilized in DESeq2 to determine changes in gene expression under the different treatment conditions. Multiple test correction was performed using the Benjamini-Hochberg procedure [3] with a significance threshold of 10%. A gene was considered DE if at least one of its transcripts was DE and had an absolute log 2 fold change > 0.25. The model corrected for the library preparation batch and the sample of origin.
Gene ontology analysis
For each treatment, we tested upregulated and downregulated genes separately for enrichment of biological processes gene ontology terms using the Fisher's test on the AmiGO 2 web browser (http:// amigo.geneontology.org/amigo). Multiple test correction was performed using the Benjamini-Hochberg procedure with a significance threshold of 5% (BH-FDR).
Identification of Differentially Accessible Regions Following Treatment
To identify differentially accessible regions, we used DESeq2 [30] (R version 3.2.1, DESeq2 version 1.8.1). We separated the genome into 300bp regions and coverageBed was used to count reads in these regions. A total of 508,140 regions with > 0.25 reads per million (high accessibility regions) were then utilized in DESeq2 using the following model:
where Y jn represents the internal DESeq2 mean accessibility parameter for region j and experiment n, M n is the treatment indicator, and β M jt parameter is the treatment effect. Differentially accessible regions (DAR) following exposure to dexamethasone, retinoic acid, caffeine, and selenium, were determined at BH FDR < 10%. We annotated the genomic context of these DARs using chromHMM [16] , which characterizes chromatin states on the basis of histone marks. We downloaded the precomputed HUVEC annotations from ENCODE [15] . Enrichments were performed with the Fisher's Exact test. DARs were then compared to gene annotations from Ensembl version 75 to identify those that were within 50kb of a transcription start site, and a Fisher's exact test was used to test for enrichment of DARs near DE genes.
Transcription factor binding footprints
To detect which transcription factors have footprints in each condition we adapted CENTIPEDE [41] to use the fragment length information contained in the ATAC-seq in the footprint model, and to jointly use in parallel the treatment and control conditions in order to ensure that the same footprint shape is used for the same motif in both conditions.
As in CENTIPEDE, we need to start from candidate binding sites for a given motif model. For each transcription factor we scan the entire human genome (hg19) for matches to its DNA recognition motif using position weight matrix (PWM) models from TRANSFAC and JASPAR as previously described [41] . Then for each candidate location l we collect all the ATAC-seq fragments which are partitioned into four binds depending on the fragment length: 1) [39-99], 2) [100-139], 3) [140-179], 4) [180-250]. For each fragment, the two Tn5 insertion sites were calculated as the position 4bp after the 5'-end in the 5' to 3' direction. Then for each candidate motif, a matrix X was constructed to count Tn5 insertion events: each row represented a sequence match to motif in the genome (motif instance), and each column a specific cleavage site at a relative bp and orientation with respect to the motif instance. We built a matrix {X l } 4 l=1 for each fragment length bin, each using a window half-size S=150bp resulting in (2 × S + W ) × 2 columns, where W is the length of the motif in bp.
Finally, we fit the CENTIPEDE model in a subset of approximately 5,000 instances to learn footprint shapes for each factor as in [34] . Then we used CENTIPEDE to analyze the remaining motif instances in the genome and kept those with a CENTIPEDE posterior probability higher than 0.99 to denote locations where the transcription factors are bound also referred as "footprints". We further subset these bound transcription factor sites in each condition by including only transcription factors which were active genomewide, as indicated by an enrichment of binding sites in high accessibility regions (see above) compared to a randomly selected set of 500,000 chromatin regions genome-wide (not high accessible regions).
Identification of response factors and genetic variants in their binding sites
In order to identify transcription factors which are important for response to treatments, we calculated enrichment scores for each active motif in regions of differentially accessible chromatin using a Fisher's exact test. We defined motifs that were significantly enriched or depleted in opening or closing chromatin (nominal p-value < 0.05, Table S3 ). For each tissue and in each treatment, we then annotated each SNP from the 1000 Genomes project [20] as 1) not in a footprint for a treatment response factor; 2) in a footprint for a treatment response factor ( Supplementary Table S2 ). SNPs in footprints are generally enriched in eQTLs [53] . Thus, to account for this treatment-independent effect, we also generated an annotation for SNPs in active footprints from the control condition, which should represent a baseline annotation of candidate regulatory variants.
Enrichment of GTEx eQTL and CAD variants in footprints for response factors
To identify treatments for which GTEx eQTLs [1] are enriched in footprints for response factors, we focused on the three artery tissues present in GTEx: tibial, coronary, and aorta. GTEx identified 11,945, 4,378, and 9,203 genes with an eQTL (eGenes) in the tibial artery, coronary artery, and aorta tissues, respectively. We then used the Torus package [53] with the "-est" option to calculate the enrichment of eQTLs in response factors for each treatment. Torus quantitatively assesses the enrichment of molecular annotations (e.g. SNPs in response factors) in GWAS or eQTL datasets. Here we used the annotations generated above for SNPs in footprints for response factors and control. As additional annotation, we included distance of the SNP to the transcriptional start site of the gene. We meta-analyzed the enrichments for each treatment across tissues using a fixed effects model with inverse variance weights. For the CAD enrichment, we used the same annotations as above on the summary statistics of the CAD GWAS, minus the distance of the SNP to the transcriptional start site of a gene. GWAS SNPs were partitioned into blocks based on LD pattern.
Colocalization
We performed colocalization as previously described using enloc [54] . Briefly, enloc integrates QTL annotations into GWAS analysis by calculating the enrichment of QTLs in complex trait-associated genetic variants, which is then used to identify colocalized SNPs between the two annotations. We performed the colocalization between the CARDIoGRAM CAD summary statistics and eQTLs from all GTEx tissues independently. We considered the lead SNP from a locus with a cumulative posterior inclusion probability (PIP) of greater than 0.5 to be colocalized. 168 SNPs colocalize, corresponding to 139 genes.
DNA was isolated from umbilical cords and sent to be genotyped using ultra-low sequencing performed by Gencove. In our dataset, 21 of the colocalized SNPs (corresponding to 14 eGenes) are polymorphic and therefore can be tested for reQTL.
reQTL mapping
For reQTL mapping of the colocalized GTEx and CAD GWAS SNPs, we tested all 21 SNPs for reQTLs, corresponding to 33 gene-SNP pairs. We used a linear model to identify reQTLs, testing for the effect of genotype dosage on quantile-normalized gene expression fold change between treatment and control. We generated an empirical null distribution by permuting sample labels, and corrected the treatment p-values based on the ranks observed in the permutation. We performed 2,820 permutations, corresponding to 3x the number of tests in the treated samples.
Accession numbers for sequencing data
Data upload to dbGaP ID phs001176.v1.p1 is pending.
Additional Files
See supplementary tables and figures for additional results. Table S2 : 1000 Genomes SNP annotations. We have annotated 1000 Genomes SNPs on the basis of whether they are within (1) or not within (0) a response factor footprint for each treatment. Column 1 is the SNP ID including chromosome and position, column 2 -6 are annotations for dexamethasone, caffeine, selenium, retinoic acid, and control, respectively. http://genome.grid.wayne.edu/FUNGEI/data_tables/FUNGEI_anno.v2.combined_1_2.active.gz Table S3 : Enrichment of footprints in DARs. For retinoic acid (A), dexamethasone (B), caffeine (C), and selenium (D), we have included the motif enrichment in DARs in both opening and closing chromatin. Columns 1-18 are: 1) Motif ID, 2) Transcription factor name, 3) Odds ratio from Fisher's exact test for opening DARs, 4) Lower bound of 95% confidence interval of odds ratio for opening DARs, 5) Upper bound of 95% confidence interval of odds ratio for opening DARs, 6) P-value from Fisher's exact test for opening DARs, 7) Number of footprints in opening DARs, 8) Number of footprints in regions tested for differential accessibility that are not opening DARs, 9) Number of opening DARs without footprint, 10) Number of regions tested for differential accessibility without opening DARs and without footprint, 11) Odds ratio from Fisher's exact test for closing DARs, 12) Lower bound of 95% confidence interval of odds ratio for closing DARs, 13) Upper bound of 95% confidence interval of odds ratio for closing DARs, 14) P-value from Fisher's exact test for closing DARs, 15) Number of footprints in closing DARs, 16) Number of footprints in regions tested for differential accessibility that are not closing DARs, 17) Number of closing DARs without footprint, 18) Number of regions tested for differential accessibility without closing DARs and without footprint A) http://genome.grid.wayne.edu/FUNGEI/data_tables/Retinoic_Acid_all_Fisher.tab B) http://genome.grid.wayne.edu/FUNGEI/data_tables/Dexamethasone_all_Fisher.tab C) http://genome.grid.wayne.edu/FUNGEI/data_tables/Caffeine_all_Fisher.tab D) http://genome.grid.wayne.edu/FUNGEI/data_tables/Selenium_all_Fisher.tab Table S4 : Colocalization results.This file includes the output from the colocalization with enloc. Columns 1-9 are: 1) eQTL signal ID 2) eQTL posterior inclusion probability (PIP) 3) GWAS PIP 4) number of SNPs in the group 5) original enloc regional colocalization probability (RCP) 6) experimental enloc PIP 7) lead SNP in the signal group 8) SNP-level colocalization probability for the lead SNP 9) tissue. http://genome.grid.wayne.edu/FUNGEI/data_tables/Torus_output_tissues.txt Figure S2 : Torus enrichment of response factor SNPs in GTEx Tibial Artery eQTLs Enrichment of GTEx eQTLs in SNPs within response factor footprints in each treatment. This is identical to Figure 3A , but includes the enrichment in the control condition.
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